Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents
Abstract: In the last decade, there has been a surge in developing immunotherapies to enhance the immune system's ability to eliminate tumor cells. Bispecific antibodies known as T cell engagers (TCEs) present an attractive strategy in this pursuit. TCEs aim to guide cytotoxic T cells toward tumor cells, thereby inducing a strong activation and subsequent tumor cell lysis. In this study, we investigated the activity of different TCEs on both conventional alpha‐beta (αβ) T cells and unconventional gamma delta (γδ) T cells. TCEs were built using camelid single‐domain antibodies (VHHs) targeting the tumor‐associated antigen CEACAM5 (CEA), together with T cell receptor chains or a CD3 domain. We show that Vγ9Vδ2 T cells display stronger in vitro antitumor activity than αβ T cells when stimulated with a CD3xCEA TCE. Furthermore, restricting the activation of fresh human peripheral T cells to Vγ9Vδ2 T cells limited the production of protumor factors and proinflammatory cytokines, commonly associated with toxicity in patients. Taken together, our findings provide further insights that γδ T cell‐specific TCEs hold promise as specific, effective, and potentially safe molecules to improve antitumor immunotherapies.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents ; day:28 ; month:05 ; year:2024 ; extent:14
European journal of immunology ; (28.05.2024) (gesamt 14)
- Creator
-
Boutin, Lola
Barjon, Clément
Chauvet, Morgane
Lafrance, Laura
Senechal, Eric
Bourges, Dorothée
Vigne, Emmanuelle
Scotet, Emmanuel
- DOI
-
10.1002/eji.202350773
- URN
-
urn:nbn:de:101:1-2405281419263.575920975924
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boutin, Lola
- Barjon, Clément
- Chauvet, Morgane
- Lafrance, Laura
- Senechal, Eric
- Bourges, Dorothée
- Vigne, Emmanuelle
- Scotet, Emmanuel
Other Objects (12)
Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
T-cell repertoire diversity: friend or foe for protective antitumor response?
Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Immunotherapeutic advances in gastrointestinal malignancies
Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
Correction: Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
Harnessing the power of a novel gene to combat Asian soybean rust: a promising breakthrough
Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
T-cell repertoire diversity: friend or foe for protective antitumor response?
Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Immunotherapeutic advances in gastrointestinal malignancies
Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
Correction: Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
Harnessing the power of a novel gene to combat Asian soybean rust: a promising breakthrough
Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
T-cell repertoire diversity: friend or foe for protective antitumor response?
Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Immunotherapeutic advances in gastrointestinal malignancies
Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
Correction: Harnessing the Electrochemical Effects of Electroporation-Based Therapies to Enhance Anti-tumor Immune Responses
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine